MAPT and neurodegenerative disease: Therefore, future studies will target motor and cognitive behaviors, downstream markers of proinflammatory activation (i.e., cyclooxygenase‐2 protein expression), and traditional biomarkers of neurodegenerative diseases, such as Lewy body or tau protein accumulation.